Clinical course of abdominal aortic aneurysms in Behçet disease: a retrospective analysis.


Journal

Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 29 01 2019
accepted: 13 03 2019
pubmed: 20 3 2019
medline: 4 1 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

Arterial aneurysms are rare manifestations of Behçet Disease (BD) with high morbidity and mortality. This study aimed to investigate the clinical course of BD patients with abdominal aortic aneurysms (AAA). We retrospectively searched charts of BD patients, followed up between 1988 and 2011, to identify those with AAA with at least 6-month clinical and radiological follow-up data. Chart review revealed 12 patients (11 males) with AAA amongst 1224 patients; follow-up data from 11 patients were available. The most common symptoms were lower back and abdominal pain. The only pre-treatment complication was a spontaneous rupture. All but one patient received corticosteroid and cyclophosphamide pulses for the induction, and corticosteroid and azathioprine for the maintenance treatment; one patient received only the maintenance treatment. Two patients had surgical graft interposition, without postoperative complications. Seven patients had endovascular stenting; five of them (71.4%) showed radiological regression after 32.5 (13.4-53.8) months, while four (57%) had clinical improvement after 11.8 (0.2-29.4) months. However, one non-responsive patient developed stent infection and exsanguinated during percutaneous drainage, and one patient developed femoral artery pseudo-aneurysm at the catheter insertion site. Another patient developed a new aneurysm under the maintenance treatment. Medical treatment alone yielded radiological regression in one of two patients. Current immunosuppressive, surgical or endovascular approaches can provide clinical and radiological improvements lately in BD patients with AAA. Furthermore, complication rates seem to be high with interventional approaches. These findings suggest an unmet need for safer alternative treatments.

Identifiants

pubmed: 30888471
doi: 10.1007/s00296-019-04283-y
pii: 10.1007/s00296-019-04283-y
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Immunosuppressive Agents 0
Cyclophosphamide 8N3DW7272P
Azathioprine MRK240IY2L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1061-1067

Références

AJR Am J Roentgenol. 1999 Mar;172(3):729-33
pubmed: 10063870
Ann Surg. 1999 Sep;230(3):289-96; discussion 296-7
pubmed: 10493476
Ann Vasc Surg. 2000 Mar;14(2):152-7
pubmed: 10742430
Rheumatology (Oxford). 2001 Apr;40(4):472-3
pubmed: 11312389
Clin Exp Rheumatol. 2001 Sep-Oct;19(5 Suppl 24):S6-12
pubmed: 11760403
Medicine (Baltimore). 2003 Jan;82(1):60-76
pubmed: 12544711
Isr Med Assoc J. 2004 Mar;6(3):152-5
pubmed: 15055270
Am J Med. 2004 Dec 1;117(11):867-70
pubmed: 15589493
Yonsei Med J. 2005 Oct 31;46(5):625-8
pubmed: 16259058
Eur J Vasc Endovasc Surg. 2008 Feb;35(2):173-80
pubmed: 17964825
Ann Rheum Dis. 2008 Dec;67(12):1656-62
pubmed: 18245110
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Curr Opin Rheumatol. 2011 Jan;23(1):24-31
pubmed: 21124084
J Vasc Surg. 2012 Jan;55(1):157-63
pubmed: 21944910
Ann Vasc Surg. 2012 Feb;26(2):277.e5-9
pubmed: 22188938
Medicine (Baltimore). 2012 Jan;91(1):18-24
pubmed: 22198498
Rheumatology (Oxford). 2014 Nov;53(11):2018-22
pubmed: 24907156
Rheumatol Int. 2015 Feb;35(2):367-70
pubmed: 24957970
N Engl J Med. 2014 Nov 27;371(22):2101-8
pubmed: 25427112
Curr Opin Cardiol. 2015 Nov;30(6):566-73
pubmed: 26352243
Immunity. 2017 Nov 21;47(5):959-973.e9
pubmed: 29150241
Ann Rheum Dis. 2018 Jun;77(6):808-818
pubmed: 29625968
Br Med J. 1967 Oct 28;4(5572):152-4
pubmed: 6053981
Br J Rheumatol. 1994 Jan;33(1):48-51
pubmed: 8162457
Surgery. 1997 Feb;121(2):150-6
pubmed: 9037226

Auteurs

Tuncay Sahutoglu (T)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Fatih, 34093, Istanbul, Turkey.
Department of Nephrology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, Health Sciences University, Urfa, Turkey.

Bahar Artim Esen (B)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Fatih, 34093, Istanbul, Turkey.

Murat Aksoy (M)

Division of Vascular Surgery, Department of Surgery, Istanbul University, Istanbul, Turkey.

Mehmet Kurtoglu (M)

Division of Vascular Surgery, Department of Surgery, Istanbul University, Istanbul, Turkey.

Arzu Poyanli (A)

Department of Radiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Ahmet Gul (A)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Fatih, 34093, Istanbul, Turkey. agul@istanbul.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH